1. 2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation. (September 2015) Authors: Shapira-Frommer, R.; Oza, A.; Domchek, S.M.; Balmana, J.; Patel, M.R.; Chen, L.M.; Drew, Y.; Burris, H.A.; Korach, J.; Flynn, M.; Bowering, V.L.; Morgan, M.A.; Watkins, S.P.; Simpson, D.; Goble, S.; Maloney, L.; Kristeleit, R. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S545 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗